-
Selective estrogen receptor modulators (SERMs) like tamoxifene and raloxifene are now well-established therapeutics, and new agents such as bazedoxifene and ospemifene have recently been introduced. These new agents have unique tissue-specific profiles that allow for a customization of therapeutic effect. In this review, the profiles of bazedoxifene and ospemifene will be compared and discussed relevant to their place in clinical practice.
-
The findings in a recent study in which investigators evaluated the relative contributions of pre-pregnant weight, weight gain in pregnancy, and the presence of gestational diabetes on the rate of large-for-gestational age fetuses has shed light on how this true complication of pregnancy can be diminished.
-
In this cross-sectional survey of 333 women, the majority reported current pubic hair removal (87%), and two-thirds reported removing all their pubic hair. Most women (60%) had experienced at least one complication because of the removal, the most common complications being epidermal abrasions and ingrown hairs.
-
Levator myalgia is a prevalent condition in women presenting with pelvic floor symptoms and is associated with greater symptom bother. Fibromyalgia is associated with an increased risk of levator ani myalgia in women presenting with prolapse.
-
In a trial comparing chemotherapy alone to chemotherapy plus bevacizumab in the treatment of patients with platinium-resistant ovarian cancer, the combination resulted in improved response rates and progression-free survival (PFS) and without a high rate of added toxicity. Whether bevacizumab alone would provide comparable improvements was not assessed but remains an important question for future trials.
-
Breast cancer survivors participating in a 12-week yoga program reported decreased fatigue, increased vitality, and improved sleep on multiple scoring systems, but no impact on depressive symptoms. Increased time spent doing yoga led to greater improvements in inflammation, mood, and fatigue.
-
In an international, randomized, non-inferiority trial, bendamustine-rituximab proved comparable in overall response rate when compared with R-CHOP or R-CVP in the management of indolent NHL and mantle cell lymphoma. Progression free and overall survival comparisons remain to be determined. Notably, toxicity profiles were significantly different, with higher rates of reported nausea and vomiting with BR and neuropathy and alopecia with R-CHOP/R-CVP.
